Pliant Therapeutics Stock
Pliant Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Bernard Coulie
- Employees
- 49
- Market cap
- $56 M
- IPO
- 03/06/2020
- Web
- pliantrx.com
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered,…
Pliant Therapeutics stock: price history
1D
-7.5%
1W
-11.8%
1M
-15.9%
6M
-32.3%
YTD
-26.2%
1Y
-45.5%
2Y
-94.0%
5Y
-95.0%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~50% stronger price swings than usual
Ask the agents about Pliant Therapeutics
Analyst assessment of Pliant Therapeutics
PRICE TARGET LOW
US$2.00
CONSENSUS
US$25.86
MEDIAN
US$38.00
PRICE TARGET HIGH
US$48.00
0
STRONG BUY
8
BUY
7
HOLD
1
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 13/03/2026
Pliant Therapeutics stock metrics
P/E
-0.6
P/B
0.38
EV/EBITDA
-0.68
RETURN ON EQUITY
-15.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.2
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.9%
FLOAT SHARES
55,033,705
AVG. DAILY VOLUME (30D)
418,815
Institutional holders
Comparable stocks
Frequently asked questions about Pliant Therapeutics stock
What does Pliant Therapeutics do?
Pliant Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Bernard Coulie, the company employs around 49 people.
The IPO was on 03/06/2020; the stock trades on NASDAQ under the ticker PLRX.
What do analysts say about Pliant Therapeutics stock?
16 analysts rate the stock, the consensus is Buy (as of 13/03/2026).
The average price target is US$25.86, ranging from US$2.00 to US$48.00, with a median of US$38.00.
This is an external assessment, not a statement by Market Jury.
When does Pliant Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 50% stronger than usual.
Does Pliant Therapeutics pay a dividend?
No, Pliant Therapeutics currently does not pay a dividend.
Which stocks are comparable to Pliant Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Pliant Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pliant Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.